文献速递血脂与心血管预防

Evolocumab在高胆固醇血症患者中的长期疗效与安全性:OSLER-1试验

Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

OSLER-1开放标签研究评估evolocumab联合标准治疗在高胆固醇血症患者中长达5年的疗效与安全性。1,255例患者纳入安全性分析,1,151例进入全evolocumab期。结果显示LDL-C持续降低约56%,严重不良事件年发生率6.9%-7.9%,与对照期6.8%相当,未检出中和抗体。

要点

  • evolocumab联合标准治疗持续降低LDL-C约56%,5年内疗效稳定。
  • 严重不良事件年发生率6.9%-7.9%,与标准治疗期6.8%相当。
  • 因不良事件停药率5.7%,未检出中和抗体。

核心结论

  • OSLER-1试验表明evolocumab在长达5年的治疗中持续显著降低LDL-C,耐受性和安全性良好,未检出中和抗体。

研究设计与样本

  • 开放标签研究,患者第1年随机接受标准治疗或evolocumab 420 mg每月一次联合标准治疗,此后可进入全evolocumab期再治疗4年。
  • 安全性分析人群1,255例, efficacy分析人群1,151例,总观察4.951患者年。

主要发现

  • evolocumab联合标准治疗在随机化后约2、3、4、5年时LDL-C分别降低56%±0.6%、57%±0.8%、56%±0.8%、56%±0.8%。
  • 平均基线LDL-C从140 mg/dl降至治疗中的61 mg/dl。
  • evolocumab联合标准治疗期间严重不良事件年发生率为6.9%至7.9%,标准治疗第1年为6.8%。
  • 因不良事件停用evolocumab的患者占5.7%。
  • 2例标准治疗和2例evolocumab联合标准治疗患者出现新发一过性结合型抗药抗体,未观察到中和抗体。

临床怎么用

  • 对于高胆固醇血症患者,evolocumab 420 mg每月一次联合标准治疗可长期稳定降低LDL-C,且严重不良事件发生率与标准治疗相当。

局限性

  • 研究为开放标签设计,第1年后无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk patients over <3 years median treatment duration. OBJECTIVES: The OSLER-1 trial (Open Label Study of Long Term Evaluation Against LDL-C Trial) evaluated longer-term effects of evolocumab during open-label hypercholesterolemia treatment for up to 5 years. METHODS: Patients randomized to standard of care (SOC) or evolocumab 420 mg monthly (evolocumab + SOC) for year 1. After year 1, patients could enter the all-evolocumab period and receive evolocumab + SOC for an additional 4 years. The authors analyzed the persistence of lipid effects and exposure-dependent safety focusing on yearly rates of adverse events (AEs) and anti-drug antibodies over 4.951 patient-years of observation. RESULTS: A total of 1,255 patients (safety analysis population) randomized into the year 1 SOC-controlled period and received ≥1 evolocumab dose (mean ± SD age 57 ± 12 years; 53% female). A total of 1,151 patients (efficacy analysis population) progressed to the all-evolocumab period (year 2 and beyond). Evolocumab + SOC persistently lowered mean ± SE low-density lipoprotein cholesterol (LDL-C) by 56% ± 0.6% (n = 1,071), 57% ± 0.8% (n = 1,001), 56% ± 0.8% (n = 943), and 56% ± 0.8% (n = 803) after approximately 2, 3, 4, and 5 years, respectively, from randomization. Mean baseline LDL-C decreased from 140 to 61 mg/dl on treatment. Yearly serious AE rates during evolocumab + SOC ranged from 6.9% to 7.9%, comparable to the 6.8% rate in SOC patients during year 1. Evolocumab discontinuation due to AEs occurred in 5.7% of patients. Two SOC and 2 evolocumab + SOC patients developed new, transient, binding anti-drug antibodies; no neutralizing antibodies were observed. CONCLUSIONS: The OSLER-1 trial demonstrated consistently excellent LDL-C-lowering efficacy, tolerance, and safety of evolocumab, with no neutralizing antibodies detected, throughout the longest-duration study of a PCSK9 inhibitor reported to date. (Open Label Study of Long Term Evaluation Against LDL-C Trial [OSLER-1]; NCT01439880).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Koren MJ, Sabatine MS, Giugliano RP, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019. PMID: 31648705. doi:10.1016/j.jacc.2019.08.1024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。